Evaluating bempedoic acid for the treatment of hyperlipidaemia

References

• Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland coronary prevention study group. N Engl J Med. 1995;333:1301–1307.
   PubMed Web of Science ®Google Scholar
• The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet. 1994;344:1383–1389.
   PubMed Web of Science ®Google Scholar
• Hobbs FD, Banach M, Mikhailidis DP, et al. Is statin-modified reduction in lipids the most important preventive therapy for cardiovascular disease? A pro/con debate. BMC Med. 2016;14:4.
   PubMed Web of Science ®Google Scholar
• Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–1278.
   PubMed Web of Science ®Google Scholar
• Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387–2397.
   PubMed Web of Science ®Google Scholar
• Serban MC, Banach M, Mikhailidis DP. Clinical implications of the IMPROVE-IT trial in the light of current and future lipid-lowering treatment options. Expert Opin Pharmacother. 2016;17:369–380.
   PubMed Web of Science ®Google Scholar
• Banach M, Nikolic D, Rizzo M, et al. IMPROVE-IT: what have we learned? Curr Opin Cardiol. 2016;31:426–433.
   PubMed Web of Science ®Google Scholar
• Saleheen D, Scott R, Javad S, et al. Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study. Lancet Diabetes Endocrinol. 2015;3:507–513.
   PubMed Web of Science ®Google Scholar
• Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1489–1499.
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1500–1509.
   PubMed Web of Science ®Google Scholar
• Banach M, Aronow WS, Serban MC, et al. Lipids, blood pressure and kidney update 2015. Lipids Health Dis. 2015;14:167.
   PubMed Web of Science ®Google Scholar
• Dragan S, Serban MC, Banach M. Proprotein convertase subtilisin/kexin 9 inhibitors: an emerging lipid-lowering therapy? J Cardiovasc Pharmacol Ther. 2015;20:157–168.
   PubMed Web of Science ®Google Scholar
• Banach M, Serban MC. Discussion around statin discontinuation in older adults and patients with wasting diseases. J Cachexia Sarcopenia Muscle. 2016;7:396–399.
   PubMed Web of Science ®Google Scholar
• Banach M, Rizzo M, Toth PP, et al. Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Expert Opin Drug Saf. 2015;14:935–955.
   PubMed Web of Science ®Google Scholar
• Sampson UK, Fazio S, Linton MF. Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges. Curr Atheroscler Rep. 2012;14:1–10.
   PubMed Web of Science ®Google Scholar
• Katsiki N, Nikolic D, Montalto G, et al. The role of fibrate treatment in dyslipidemia: an overview. Curr Pharm Des. 2013;19:3124–3131.
   PubMed Web of Science ®Google Scholar
• Patel J, Martin SS, Banach M. Expert opinion: the therapeutic challenges faced by statin intolerance. Expert Opin Pharmacother. 2016;17:1497–1507.
   PubMed Web of Science ®Google Scholar
• Pinkosky SL, Newton RS, Birch CM, et al. Abstract 17608: identification of a tissue-specific very long-chain Acyl-CoA synthetase involved in the inhibition of ATP-Citrate Lyase (ACL) by ETC-1002: a novel mechanism for cholesterol biosynthesis inhibition in the liver. Circulation. 2015;132:A17608.
   Web of Science ®Google Scholar
• Nikolic D, Mikhailidis DP, Davidson MH, et al. ETC-1002: a future option for lipid disorders? Atherosclerosis. 2014;237:705–710.
   PubMed Web of Science ®Google Scholar
• Pinkosky SL, Newton RS, Ea D, et al. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. Nature Commun. 2016;7:13457.
   PubMed Web of Science ®Google Scholar
• Lemus HN, Mendivil CO. Adenosine triphosphate citrate lyase: emerging target in the treatment of dyslipidemia. J Clin Lipidol. 2015;9:384–389.
   PubMed Web of Science ®Google Scholar
• Li MN, Guo X, Bao PJ, et al. Association of genetic variations in the ACLY gene with growth traits in Chinese beef cattle. Genet Mol Res. 2016;15:gmr8250.
   Web of Science ®Google Scholar
• Bouchard-Mercier A, Rudkowska I, Lemieux S, et al. Polymorphisms, de novo lipogenesis, and plasma triglyceride response following fish oil supplementation. J Lipid Res. 2013;54:2866–2873.
   PubMed Web of Science ®Google Scholar
• Pinkosky SL, Filippov S, Srivastava RA, et al. AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism. J Lipid Res. 2013;54:134–151. Epub 2012 Nov 3.
   PubMed Web of Science ®Google Scholar
• Melton EM, Cerny RL, Watkins PA, et al. Human fatty acid transport protein 2a/very long chain acyl-CoA synthetase 1 (FATP2a/Acsvl1) has a preference in mediating the channeling of exogenous n-3 fatty acids into phosphatidylinositol. J Biol Chem. 2011;286:30670–30679.
   PubMed Web of Science ®Google Scholar
• Parker BA, Gregory SM, Lorson L, et al. A randomized trial of coenzyme Q10 in patients with statin myopathy: rationale and study design. J Clin Lipidol. 2013;7:187–193.
   PubMed Web of Science ®Google Scholar
• Lawrence J, Moyer C, Ameri M, et al. Abstract 13907: statin-induced myopathy is mediated by isoprenoid depletion and is independent of serum cholesterol levels. Circulation. 2014;130:A13907.
   Web of Science ®Google Scholar
• Gluba-Brzozka A, Franczyk B, Toth PP, et al. Molecular mechanisms of statin intolerance. Arch Med Sci. 2016;12:645–658.
   PubMed Web of Science ®Google Scholar
• Muntean DM, Thompson PD, Catapano AL, et al. Statin-associated myopathy and the quest for biomarkers: can we effectively predict statin-associated muscle symptoms? Drug Discovery Today. 2016; in press. DOI:10.1016/j.drudis.2016.09.001
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Davidson M, MacDougall D, et al. ETC-1002 lowers LDL-C and beneficially modulates other cardio-metabolic risk factors in hypercholesterolemic subjects with either normal or elevated triglycerides. J Am Coll Cardiol. 2012;59:E1625–E.
   Web of Science ®Google Scholar
• Ballantyne CM, Davidson MH, Macdougall DE, et al. Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. J Am Coll Cardiol. 2013;62:1154–1162. Epub 2013 Jun 19.
   PubMed Web of Science ®Google Scholar
• Gutierrez MJ, Rosenberg NL, Macdougall DE, et al. Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol-lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol. 2014;34:676–683. Epub 2014 Jan 5.
   PubMed Web of Science ®Google Scholar
• Thompson PD, Rubino J, Janik MJ, et al. Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance. J Clin Lipidol. 2015;9:295–304. Epub 2015 Jun 16.
   PubMed Web of Science ®Google Scholar
• Esperion Therapeutics. Evaluation of ETC-1002 in patients with hypercholesterolemia and hypertension. Clinical trial.gov protocol. 2015. Available from: https://clinicaltrials.gov/show/NCT02178098
   Google Scholar
• Newton RS, Ballantyne CM, Thompson PD, et al. ETC-1002 lowers LDL-cholesterol and is well tolerated in hypercholesterolaemic patients across four phase 2a studies. NLA Scientific Sessions 2014; Orlando, FL, USA. 2014 May 1–4.Abstract 155.
   Google Scholar
• Ballantyne CM, McKenney JM, MacDougall DE, et al. Effect of ETC-1002 on serum low-density lipoprotein cholesterol in hypercholesterolemic patients receiving statin therapy. Am J Cardiol. 2016;117:1928–1933.
   PubMed Web of Science ®Google Scholar
• Thompson PD, MacDougall DE, Newton RS, et al. Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance. J Clin Lipidol. 2016;10:556–567.
   PubMed Web of Science ®Google Scholar
• Esperion Therapeutics. Evaluation of long-term safety and tolerability of ETC-1002 in high-risk patients with hyperlipidemia and high CV risk. Clinical trial.gov protocol. 2016. Available from: https://clinicaltrials.gov/show/NCT02666664
   Google Scholar
• Mampuya WM, Frid D, Rocco M, et al. Treatment strategies in patients with statin intolerance: the Cleveland clinic experience. Am Heart J. 2013;166:597–603. Epub 2013 Sep 11.
   PubMed Web of Science ®Google Scholar
• Esperion Therapeutics. Esperion therapeutics announces positive top-line phase 2 results for ETC-1002 in patients with hypercholesterolemia and hypertension. 2015. Available from: http://investor.esperion.com/releasedetail.cfm?ReleaseID=924113
   Google Scholar
• Cromwell WC, Otvos JD, Keyes MJ, et al. LDL particle number and risk of future cardiovascular disease in the framingham offspring study - implications for LDL management. J Clin Lipidol. 2007;1:583–592.
   PubMed Web of Science ®Google Scholar
• Gondeck K. LDL particle number and size. Measurement as a strategy for CAD prevention. Adv Nps Pas. 2012;3:26–28.
   PubMedGoogle Scholar
• Matyus SP, Braun PJ, Wolak-Dinsmore J, et al. NMR measurement of LDL particle number using the Vantera Clinical Analyzer. Clin Biochem. 2014;47:203–210.
   PubMed Web of Science ®Google Scholar
• Kucera M, Oravec S, Hirnerova E, et al. Effect of atorvastatin on low-density lipoprotein subpopulations and comparison between indicators of plasma atherogenicity: a pilot study. Angiology. 2014;65:794–799.
   PubMed Web of Science ®Google Scholar
• Banach M, Malodobra-Mazur M, Gluba A, et al. Statin therapy and new-onset diabetes: molecular mechanisms and clinical relevance. Curr Pharm Des. 2013;19:4904–4912.
   PubMed Web of Science ®Google Scholar
• Chrusciel P, Sahebkar A, Rembek-Wieliczko M, et al. Impact of statin therapy on plasma adiponectin concentrations: a systematic review and meta-analysis of 43 randomized controlled trial arms. Atherosclerosis. 2016;253:194–208.
   PubMed Web of Science ®Google Scholar
• Thompson PD, Panza G, Zaleski A, et al. Statin-Associated Side Effects. J Am Coll Cardiol. 2016;67:2395–2410.
   PubMed Web of Science ®Google Scholar
• Esperion Therapeutics. A study of pharmacokinetics, pharmacodynamics and safety of adding ETC-1002 to atorvastatin 80 mg. Clinical trial.gov protocol. 2016. Available from: https://clinicaltrials.gov/show/NCT02659397
   Google Scholar
• Esperion Therapeutics. Esperion therapeutics provides clinical development and regulatory update for bempedoic acid. 2016. Available from: https://globenewswire.com/news-release/2016/06/28/852085/0/en/Esperion-Therapeutics-Provides-Clinical-Development-and-Regulatory-Update-for-Bempedoic-Acid.html
   Google Scholar